Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
20 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Veracyte, Inc.’s names, not what it holds today.
Patents granted
20
20 utility, 1976 to Dec 31, 2025
Granted in 2025
5
Against 2 in 2024 and 1 in 2023
Applications published
64
8 of them in 2025
Names they are printed under
4
its own name, a subsidiary
By yearGrantedApplications published
'11'12'13'14'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology5
Computer technology4
Medical technology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
Veracyte, Inc. its own name
named as the applicant on its applications, in US. 1 more under the same name are not counted (printed in FR)
51 publishedVeracyte, Inc. its own name
US, as the owner printed on each patent
8 publishedVeracyte SD, Inc. a subsidiary
named as the applicant on its applications, in US
4 publishedVeracyte SD, Inc. a subsidiary
US, as the owner printed on each patent
1 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Dec 16, 2025 | 12,497,660 | Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy | Medical technology | Veracyte SD, Inc. |
| Aug 5, 2025 | 12,378,610 | Systems and methods for preprocessing target data and generating predictions using a machine learning model | Computer technology | Veracyte SD, Inc. |
| May 20, 2025 | 12,305,238 | Methods for treatment of thyroid cancer | Computer technology | Veracyte, Inc. |
| May 13, 2025 | 12,297,505 | Algorithms for disease diagnostics | Computer technology | Veracyte, Inc. |
| May 13, 2025 | 12,297,503 | Methods for classification of tissue samples as positive or negative for cancer | Biotechnology | Veracyte, Inc. |
| Oct 8, 2024 | 12,110,554 | Methods for classification of tissue samples as positive or negative for cancer | Biotechnology | Veracyte, Inc. |
| May 7, 2024 | 11,976,329 | Methods and systems for detecting usual interstitial pneumonia | Biotechnology | Veracyte, Inc. |
| May 2, 2023 | 11,639,527 | Methods for nucleic acid sequencing | Biotechnology | Veracyte, Inc. |
| Jan 4, 2022 | 11,217,329 | Methods and systems for determining biological sample integrity | Computer technology | Veracyte, Inc. |
| Mar 2, 2021 | 10,934,587 | Methods and compositions for diagnosis of thyroid conditions | Biotechnology | Veracyte, Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Oct 23, 2025 | 2025/0327136 | SYSTEMS AND METHODS FOR PREPROCESSING TARGET DATA AND GENERATING PREDICTIONS USING A MACHINE LEARNING MODEL | Computer technology | Veracyte SD, Inc. |
| Oct 2, 2025 | 2025/0308632 | PROGNOSIS AND TREATMENT OF MOLECULAR SUBTYPES OF PROSTATE CANCER | Pharmaceuticals | Veracyte, Inc. |
| Oct 2, 2025 | 2025/0305051 | SYSTEMS AND METHODS OF DIAGNOSING IDIOPATHIC PULMONARY FIBROSIS | Biotechnology | Veracyte, Inc. |
| Aug 21, 2025 | 2025/0263795 | METHODS FOR CLASSIFICATION OF TISSUE SAMPLES AS POSITIVE OR NEGATIVE FOR CANCER | Biotechnology | Veracyte, Inc. |
| May 29, 2025 | 2025/0171854 | GENETIC SIGNATURES TO PREDICT PROSTATE CANCER METASTASIS AND IDENTIFY TUMOR AGGRESSIVENESS | Analysis of biological materials | Veracyte, Inc. |
| May 15, 2025 | 2025/0156731 | SYSTEMS AND METHODS FOR PREPROCESSING TARGET DATA AND GENERATING PREDICTIONS USING A MACHINE LEARNING MODEL | Computer technology | Veracyte SD, Inc. · patent 12,378,610 granted from it |
| Jan 30, 2025 | 2025/0037869 | METHODS AND COMPOSITIONS FOR CLASSIFICATION OF SAMPLES | Computer technology | Veracyte, Inc. |
| Jan 30, 2025 | 2025/0034646 | METHODS FOR TREATMENT OF THYROID CANCER | Computer technology | Veracyte, Inc. · patent 12,305,238 granted from it |
| Dec 26, 2024 | 2024/0425927 | METHODS FOR CLASSIFICATION OF TISSUE SAMPLES AS POSITIVE OR NEGATIVE FOR CANCER | Biotechnology | Veracyte, Inc. · patent 12,297,503 granted from it |
| Dec 19, 2024 | 2024/0417800 | USE OF A GENETIC SIGNATURE DIAGNOSTICALLY TO EVALUATE TREATMENT STRATEGIES FOR PROSTATE CANCER | Organic fine chemistry | Veracyte, Inc. |
What it applied for, 2024 to 2025: Computer technology 6 · Biotechnology 4 · Medical technology 1 · Organic fine chemistry 1 · Analysis of biological materials 1 · Pharmaceuticals 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.